

14 September 2007

TO: MEDICAL GROUPS, DHB HOSPITAL PHARMACIES AND INTERESTED PARTIES

**CONSULTATION ON TENDER OF CERTAIN PHARMACEUTICALS
ALL RESPONSES DUE BY 5PM, 26 OCTOBER 2007**

In accordance with PHARMAC's objective of securing for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided, PHARMAC is consulting on the possibility of tendering for Sole Subsidised Supply and/or Hospital Supply Status of certain pharmaceuticals listed in Schedule One of this document.

Attached to this letter is a list of pharmaceuticals that we are considering tendering for Sole Subsidised Supply to community pharmacies and/or Hospital Supply Status for supply to DHB Hospital pharmacies. Pharmaceuticals are listed alphabetically by chemical, form and strength in therapeutic groups and have a 'C' and/or 'H' next to them to indicate whether they are being tendered for community and/or hospital supply.

In general, the proposed Tender process would be similar to the 2006/07 Tender. A copy of the 2006/07 Invitation to Tender is available either on our website: www.pharmac.govt.nz, or by contacting PHARMAC.

Comments Sought

We seek comments on the approach outlined in the following pages, in particular the following:

- the proposed process and timetable;
- the actual or potential clinical implications of awarding Sole Subsidised Supply and/or Hospital Supply Status to the pharmaceuticals listed in Schedule One; and
- for hospital pharmaceuticals what the appropriate Discretionary Variance Limit for each pharmaceutical would be, where a 1% Discretionary Variance Limit is considered clinically unacceptable; and
- comments on a proposal for Sole Subsidised Supply to include access to funding for alternative brands (**Alternative Brand Access**).

Background

Since 1997 PHARMAC has been using the strategy of tendering for sole supply of pharmaceuticals for a fixed period of time. Tendering has proven to be an effective way to encourage competition among suppliers of off patent pharmaceuticals. It is proposed that the community Tender and hospital Tender processes continue to be run in unison, however the pharmaceutical list for community and hospital pharmacies may be different.

Key Aspects of Awarding a Tender for Community Pharmaceuticals:

- For the community pharmaceuticals the Tender winning brand would be the only subsidised brand for approximately 2½ years. The Sole Subsidised Supply period would conclude on 30 June 2011 for all awarded Tenders.
- The Sole Subsidised Supply brand would be fully subsidised for the Tender period which means a pharmaceutical that currently carries a manufacturer's surcharge (that is the additional patient charge above that of the patient co-payment), would become fully subsidised if a Tender was awarded.
- No other brand of the pharmaceutical could be listed (or subsidised) on the Pharmaceutical Schedule during the Tender period (subject to any Alternative Brand Access, as proposed).
- Other brands could continue to be marketed, sold and dispensed in New Zealand, however they would not receive a Government subsidy.

Key Aspects of Awarding a Tender for the DHB Hospital Pharmaceuticals:

- For the DHB Hospital pharmaceuticals, the Hospital Supply Status brand would be the only brand DHB Hospitals could purchase (excluding any allowance for alternative brands under the agreed Discretionary Variance Limits) for approximately 2½ years. The Hospital Supply Status period would conclude on 30 June 2011 for all awarded Tenders.
- No other brand of the pharmaceutical would be listed (or purchased) on Section H of the Pharmaceutical Schedule during the Tender period except as allowed under any DV Limits.

The Process

The Tender process is run annually. The proposed timelines for the 2007/08 Tender are as follows:

Date	Event
September/October 2007	Consultation with suppliers, medical groups and interested parties on the proposed pharmaceutical list and draft Invitation to Tender.
26 October 2007	Final date for all consultation to be received.
November 2007	Meeting of Tender Medical Evaluation Subcommittee of PTAC to consider clinical issues in relation to the proposed Tender list.
Late December 2007	Issuing of the 2006/07 Invitation to Tender.
Late February 2008	Invitation to Tender closes.
From April 2008	Board decisions on the first Tender winners announced.
30 June 2011	End of the sole supply period for all pharmaceuticals where a Tender is awarded from the 2007/08 Tender. Terms after the End Date may apply.

Unresolved Tender Bids

PHARMAC would review any unresolved Tender Bids from the Invitation to Tender dated 22 December 2005 (2005/06 Tender) and the Invitation to Tender dated 15 December 2006 (2006/07 Tender) prior to issuing the 2007/08 Tender. Should any unresolved Tender Bids be declined, PHARMAC would consider re-tendering those pharmaceuticals when the Invitation to Tender is issued in December 2007. Any unresolved Tender Bids have not been included in the draft pharmaceutical list.

Contractual obligations for suppliers

A copy of the draft contractual requirements which would form the terms of the contract with successful suppliers in the 2007/08 Tender is available on the PHARMAC website: www.pharmac.govt.nz, or by phoning PHARMAC on 0800 66 00 50. The following proposed changes to the Invitation to Tender should be noted:

This year PHARMAC proposes to introduce an electronic tendering system that suppliers would be required to use in order to submit a Tender Bid(s).

Alternative Brand Access

This year we are also consulting on adding an allowance within the Tender contract for PHARMAC to provide funding for alternative brands of community pharmaceuticals (called Alternative Brand Access). This is a change from previous years' tenders, and if adopted would create a new mechanism for people to access brands of a medicine other than the one that wins the tender contract.

If the contractual allowance for Alternative Brand Access is adopted it would necessarily result in some changes to the manner in which Sole Subsidised Supply operates. As well as comments on the proposal in general, we seek particular consideration of the following questions:

- Should we allow the provision of a subsidy for an alternative brand and, if so, in what circumstances?
- What percentage allowance for alternative brands should be included within tender bids?

Background

Between 1997 and 2007 over \$300 million that would otherwise have been unavailable has been reinvested in new pharmaceuticals and other health services as a result of sole-supply tenders.

Tenders and RFPs encourage competition so that the value from pharmaceuticals is maximised (including the costs of continuous supply being underwritten).

Sole Subsidised Supply for a defined period of time is often used to generate this competition. Once Sole Subsidised Supply is awarded all other brands of that pharmaceutical are delisted from the Pharmaceutical Schedule, and are no longer subsidised.

It may be desirable, where identified as a need by PTAC (and/or relevant subcommittee), to have greater flexibility under the sole supply policy for people to access other brands when the tender-winning brand is clinically unsuitable. Alternative Brand Access recognises that while most generic products will have established "bioequivalence" to the current market leader, in some circumstances a small number of patients may experience difficulties with the change.

Currently the mechanism available for funding of alternative brands, where one brand holds Sole Subsidised Supply, is through the Community Exceptional Circumstances (CEC) process. Given its specific criteria and purpose, the CEC process typically provides funding for alternative brands very infrequently.

Possible mechanism for implementation

To enable the proposed tender contractual changes to be developed, PHARMAC has considered possible mechanisms to apply an Alternative Brand Access. We are proposing the following mechanism:

- The product list would contain an Authorised Allowance which would be the amount of an Alternative Brand of a particular pharmaceutical that could be subsidised without reimbursement to the tender winner for the reduced volume.
- An allowance in the region of 0.2 - 1% may be appropriate (where applied at all), although we welcome other views. PHARMAC would seek advice from PTAC and/or its relevant subcommittee on whether to include an allowance in each case.
- The access to funding for the alternative brand would be through a Special Authority, on an “access by application” basis.
- Applications would be considered by a panel of practicing clinicians, using the following criteria, or similar:

Evidence is provided by the patient’s doctor that:

- a. The patient was adequately managed on a previously subsidised brand, and the subsidy for that brand is being removed as a result of Sole Subsidised Supply; and
- b. There are no other suitable alternative pharmaceuticals, or all the alternatives (including dose adjustment) have had an adequate trial and failed; and
- c. The Sole Subsidised Supply brand is considered to be unsuitable because of:
 - i. A serious adverse reaction has occurred to the Sole Subsidised Supply brand ; or
 - ii. An excipient in the Sole Subsidised Supply brand that is contraindicated in the patient; or
 - iii. Lack of efficacy or intolerable side effects to the Sole Subsidised Supply brand that persist through an adequate trial of the subsidised brand, followed by reappearance of the issue on re-challenge.

Approvals would not be given for issues related to features of the product that were considered as part of the tender evaluation (e.g. physical features of the product such as flavour, coatings etc.), and would not be given if the issue arose more than 6 months after the initiation of the Sole Subsidised Supply period.

- The funding for an alternative brand would be provided on a “Cost Brand Source” basis, meaning that funding could be provided even if the product had to be sourced from overseas (i.e. if the local supplier had discontinued supply).

Lead Time

We propose to amend the Lead Time so that it is clear that the quoted Lead Time means that stock would be available to the market on the 12th prior the listing date in

the Pharmaceutical Schedule (see proposed definition of Lead Time in clause 1 of Schedule 1 of the Invitation).

Financial compensation for breach of DV limits

PHARMAC proposes to amend the minimum payment required of a DHB that breaches its DV limits, where the national DV limit has been breached, from \$5,000 per tender item to \$1,000 per tender item.

Reference Pricing

Reference pricing is based on the classification of pharmaceuticals into Therapeutic Subgroups. A Therapeutic Subgroup is defined as a set of pharmaceuticals that produce the same or similar therapeutic effect in treating the same or similar condition(s).

The draft list contains pharmaceuticals that belong in an existing Therapeutic Subgroup. In some cases, PHARMAC may be considering tendering more than one pharmaceutical in a Therapeutic Subgroup. Where this is the case it gives rise to two possible scenarios where:

- 1) It is possible that awarding Sole Subsidised Supply to one pharmaceutical could result in changes to the subsidies for other pharmaceuticals in the same Therapeutic Subgroup.
- 2) Where more than one pharmaceutical in a Therapeutic Subgroup is included on the list, PHARMAC may award Sole Subsidised Supply to each pharmaceutical (and therefore not apply reference pricing in the usual way) or may only award Sole Subsidised Supply to one pharmaceutical and apply reference pricing to the others.


Both scenarios could give rise to new or increased manufacturer surcharges.

Distribution of Consultation Documents

Please note that this consultation letter has been widely distributed however should you consider that a particular person, group or agency should receive this and future Tender documents please feel free to contact PHARMAC (also available from our website). We also invite any person or group to contact PHARMAC should you wish to have a meeting to discuss this consultation document.

Please direct any queries you may have to Mike Bignall (DDI: (04) 9167 562) at PHARMAC for questions in relation to community supply, and Andrew Davies (DDI: (04) 9167 531) for questions in relation to hospital supply.

Yours sincerely



Steffan Crausaz
Manager, Funding and Procurement

Possible pharmaceuticals for tender for sole supply

Order of pharmaceuticals in this Annex

The pharmaceuticals have been listed in therapeutic groups according to the classification system used in the Pharmaceutical Schedule. Below is a list of the groups, and the corresponding page numbers for your ease of reference. Please note that pharmaceuticals with indications that may apply to multiple therapeutic groups will only appear in one.

<i>Therapeutic Group</i>	Page Numbers
Alimentary Tract and Metabolism	8 – 10
Blood and Blood Forming Organs	10 – 12
Cardiovascular System	12 – 14
Dermatologicals	14 – 17
Extemporaneously Compounded Preparations	17
Genito-Urinary System	17
Hormone Preparations – Systemic excluding contraceptives	17 – 19
Infections – Agents for Systemic Use	19 – 23
Musculoskeletal System	23 – 24
Nervous System	24 – 29
Oncology and Immunosuppressants	29 – 31
Respiratory System and Allergies	31
Sensory Organ	31 – 33
Special Foods	33

Information provided for each pharmaceutical

For each pharmaceutical (as defined by chemical name, form and strength) we have provided the following information:

- the current ex-manufacturer subsidy per unit of measure as at 1 September 2007;
- number of subsidised or partially subsidised units sold in the community in the year ending 30 June 2007;
- estimated annual community market value at current subsidies; and
- comments specifically relating to the Tender of the line item and/or its current listing on the Pharmaceutical Schedule.

The figures for the number of units subsidised in community pharmacies are approximate and are based on the year ending June 2007. These figures are indicative only and sales are not guaranteed. PHARMAC makes no representation as to the level of sales or likely sales of any tender item. There are no figures available for hospital pharmaceuticals.

We have estimated market value by multiplying the volume of units subsidised in the year ending 30 June 2007 by the relevant listed unit subsidy as at 1 September 2007.

Patents

A number of pharmaceuticals included in this list may still be on patent. Based on information available to PHARMAC, we believe these patents will expire by within the sole supply period.

While PHARMAC has taken care in preparing the information contained in this table, it does not make any representation as to the accuracy of this information and accepts no liability in the event that the information is incorrect. Suppliers remain responsible for ensuring they do not infringe patents. Suppliers are responsible for their own independent assessment of the information and must decide for themselves whether or not to make an investment and on what terms.

Explanation of terms, symbols and abbreviations

Most terms and abbreviations used are self explanatory: “tab” means tablet, “cap” means capsule, “liq” means liquid, “inj” means injection, “suppos” means suppository, “grans” mean granules and “OP” means original pack to be dispensed.

The following table explains the symbols used in the draft pharmaceutical list:

Symbol	Explanation
Underline	Pharmaceutical line items where a sole supply contract is in force are underlined. The price and subsidy for these pharmaceuticals are fixed until 30 June 2008 unless otherwise stated in the Comments column and a listing of a new brand could only occur until after that date.
C	To be tendered for Sole Subsidised Supply (community pharmaceuticals).
H	To be tendered for Hospital Supply Status (DHB Hospital pharmaceuticals).
PCT	A reference in the Invitation to Tender to allow Pharmaceuticals Cancer Treatments to be listed in Section B of the Pharmaceutical Schedule as part of PHARMAC’s Pharmaceutical Cancer Treatments project.
+	PHARMAC has been advised of the existence of a process patent.
*	There is no fully funded product available for this line item (in relation to community supply).

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item

Units

Cost

Unit Subsidy

DV Limit

Comments

Alimentary Tract and Metabolism

Acarbose

Tab 50 mg	475,805	\$116,287	\$0.2444	C H	1%
Tab 100 mg	168,940	\$58,183	\$0.3444	C H	1%

Alfacalcidol

Cap 0.25 mcg	159,315	\$41,932	\$0.2632	C H	1%
Cap 1 mcg	41,315	\$36,349	\$0.8798	C H	1%
Oral drops 2 mcg per ml	7,125	\$21,617	\$3.0340	C H	1%

Amphotericin B

Lozenges 10 mg	281,820	\$82,573	\$0.2930	C H	1%	
Oral liq 100 mg per ml				C H	1%	Not currently listed in the Pharmaceutical Schedule

Budesonide

Cap 3 mg	43,445	\$80,373	\$1.8500	C H	1%
----------	--------	----------	----------	-----	----

Calcium

<u>Eff tab 1 g</u>	3,300,309	\$821,777	\$0.2490	C H	1%	Additional additives would be considered. Dose range of 1 g of elemental calcium is required
--------------------	-----------	-----------	----------	-----	----	----------------------------------------------------------------------------------------------

Calcium Carbonate

<u>Tab 1.25 g</u>	32,067,230	\$1,176,867	\$0.0367	C H	1%
<u>Tab 1.5 g</u>	5,095,250	\$210,434	\$0.0413	C H	1%

Calcium Carbonate with Aminoacetic Acid

Tab 420 mg with aminoacetic acid 180 mg	1,359,384	\$40,782	\$0.0300 *	C H	1%
-----------------------------------------	-----------	----------	------------	-----	----

Calcium Gluconate

Inj 10%, 10 ml	1,225	\$2,621	\$2.1398	C H	1%
----------------	-------	---------	----------	-----	----

Danthron With Poloxamer

Cap 25 mg with poloxamer 200 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule
Cap 37.5 mg with poloxamer 500 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule

Diphenoxylate Hydrochloride with Atropine Sulphate

<u>Tab 2.5 mg with atropine sulphate 25 mcg</u>	757,691	\$29,550	\$0.0390	C H	1%
-------------------------------------------------	---------	----------	----------	-----	----

Docosate Sodium

<u>Tab 50 mg</u>	791,187	\$38,689	\$0.0489	C H	1%
<u>Tab 120 mg</u>	1,292,250	\$62,028	\$0.0480	C H	1%

Ferrous Salts

Tab	6,953,179			C H	1%	Any iron salt and additives would be considered. Dose range of 60 - 105 mg elemental iron per tablet required (short-acting or long-acting)
-----	-----------	--	--	-----	----	---------------------------------------------------------------------------------------------------------------------------------------------

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Ferrous Salts with Folic Acid					
Tab with folic acid	1,001,377	\$60,083	\$0.0600 *	C H 1%	Any iron salt would be considered. Dose range of 60 - 110 mg elemental iron per tablet required (short-acting or long-acting)
Glibenclamide					
Tab 2.5 mg	418,451	\$15,817	\$0.0378	C H 1%	
Tab 5 mg	1,758,731	\$58,214	\$0.0331	C H 1%	
Gliclazide					
<u>Tab 80 mg</u>	18,260,202	\$1,331,169	\$0.0729	C H 1%	
Glipizide					
<u>Tab 5 mg</u>	13,016,532	\$455,579	\$0.0350	C H 1%	
Glucose Oxidase					
Urine Ketone Diagnostic Test				* C	Each individual product should be foil wrapped
Hyoscine N-Butylbromide					
<u>Inj 20 mg, 1 ml</u>	56,467	\$80,748	\$1.4300	C H 1%	
<u>Tab 10 mg</u>	2,600,409	\$172,927	\$0.0665 *	C H 1%	
Iron Polymaltose					
Inj 50 mg per ml, 2 ml	18,951	\$113,516	\$5.9900	C H 1%	
Magnesium Hydroxide					
Tab				C H 1%	Not currently listed in the Pharmaceutical Schedule
Mebeverine Hydrochloride					
Tab 135 mg	674,683	\$80,355	\$0.1191 *	C H 1%	
Nystatin					
<u>Oral liq 100,000 u per ml</u>	1,027,781	\$129,809	\$0.1263	C H 1%	
Olsalazine					
Cap 250 mg	206,994	\$65,224	\$0.3151	C H 1%	
Tab 500 mg	177,677	\$106,357	\$0.5986	C H 1%	
Poloxamer					
<u>Oral drops 10%</u>			\$0.1310	C H 1%	Not currently listed in the Pharmaceutical Schedule
Ranitidine Hydrochloride					
Inj 25 mg per ml, 2 ml	3,008	\$5,264	\$1.7500	C H 1%	
<u>Tab 150 mg</u>	6,093,289	\$194,985	\$0.0320	C H 1%	
<u>Tab 300 mg</u>	1,948,336	\$85,337	\$0.0438	C H 1%	
Simethicone					
Oral liq aluminium hydroxide 200 mg with magnesium hydroxide 200 mg and activated simethicone 20 mg per 5 ml	12,475,721	\$37,427	\$0.0030 *	C H 1%	
Sodium Alginate					
Oral liq 500 mg with sodium bicarbonate 267 mg per 10 ml	7,603,083	\$22,809	\$0.0030 *	C H 1%	Additional active agents would be accepted

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Sodium Bicarbonate					
Tab				C H 1%	Not currently listed in the Pharmaceutical Schedule
Sodium Cromoglycate					
Cap 100 mg	82,948	\$73,998	\$0.8921	C H 1%	
Sucralfate					
Tab 1 g	70,271	\$20,786	\$0.2958 *	C H 1%	
Tolbutamide					
Tab 500 mg	128,075	\$15,369	\$0.1200	C H 1%	
Triamcinolone Acetonide					
<u>0.1% in Dental Paste USP</u>	86,085	\$77,477	\$0.9000	C H 1%	
Ursodeoxycholic Acid					
<u>Cap 250 mg - 300 mg</u>	272,261	\$735,050	\$2.6998	C H 1%	Bids would be accepted for a tablet within this strength range
Vitamin A with Vitamins D and C					
Soln 1000 u with Vitamin D 400 u and ascorbic acid 30 mg per 10 drops	154,883	\$67,839	\$0.4380 *	C H 1%	
Zinc Sulphate					
<u>Cap 220 mg</u>	432,069	\$38,886	\$0.0900	C H 1%	
Blood and Blood Forming Organs					
Acipimox					
<u>Cap 250 mg</u>	227,496	\$142,185	\$0.6250	C H 1%	
Aprotinin					
Inj 10,000 mcg per ml, 50 ml	343	\$21,815	\$63.6000 *	C H 1%	
Inj 10,000 mcg per ml, 100 ml				C H 1%	Not currently listed in the Pharmaceutical Schedule
Inj 10,000 mcg per ml, 200 ml				C H 1%	Not currently listed in the Pharmaceutical Schedule
Bezafibrate					
<u>Tab 200 mg</u>	1,552,178	\$151,803	\$0.0978	C H 1%	
Calcium Polystyrene Sulphonate					
Powder	441,197	\$249,806	\$0.5662	C H 1%	
Cholestyramine with Aspartame					
Sachets 4 g with aspartame	161,633	\$62,229	\$0.3850 *	C H 1%	
Dextrose					
Inj 50%, 10 ml	11,839	\$65,115	\$5.5000 *	C H 1%	
Dipyridamole					
Tab 25 mg	373,841	\$710	\$0.0019 *	C H 1%	
<u>Tab long-acting 150 mg</u>	7,180,541	\$1,378,664	\$0.1920	C H 1%	
Enoxaparin Sodium					
Inj 20 mg per 0.2 ml				H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Enoxaparin Sodium							
Inj 40 mg per 0.4 ml					H 1%		
Inj 60 mg per 0.6 ml					H 1%		
Inj 80 mg per 0.8 ml					H 1%		
Inj 100 mg per ml, 1 ml					H 1%		
Inj 120 mg per 0.8 ml					H 1%		
Inj 150 mg per ml, 1 ml					H 1%		
Gemfibrozil							
Cap 300 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
Tab 600 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule	
Heparin Sodium							
Inj 1,000 iu per ml, 5 ml	1,243	\$1,661	\$1.3360		C H 1%		
Inj 1,000 iu per ml, 35 ml	6,482	\$78,432	\$12.1000		C H 1%		
Inj 5,000 iu per ml, 1 ml	7,384	\$15,241	\$2.0640		C H 1%		
Inj 5,000 iu per ml, 5 ml	16,955	\$46,965	\$2.7700 *		C H 1%		
Inj 25,000 iu per ml, 0.2 ml	5,207	\$7,811	\$1.5000 *		C H 1%		
Heparinised Saline							
Inj 100 iu per ml, 5 ml	3,900	\$8,093	\$2.0752		C H 1%		
Phosphate Supplement							
Tab 315 mg with sodium acid phosphate 1.937 g and sodium bicarbonate 350 mg, effervescent	55,852	\$41,889	\$0.7500		C		
Phytomenadione							
Inj 2 mg per 0.2 ml	6,441	\$10,306	\$1.6000		C H 1%		
Inj 10 mg per ml, 1 ml	2,520	\$4,642	\$1.8420		C H 1%		
Tab 10 mg	57,915	\$32,432	\$0.5600		C H 1%		
Potassium Chloride							
<u>Inj 75 mg per ml, 10 ml</u>	17,358	\$9,026	\$0.5200		C H 1%		
<u>Inj 150 mg per ml, 10 ml</u>	9,313	\$4,843	\$0.5200		C H 1%		
Pravastatin							
Tab 10 mg			\$0.9153		C H 1%		
Tab 20 mg			\$1.4193		C H 1%		
Tab 40 mg			\$2.1770		C H 1%		
Tab 80 mg					C H 1%	Not currently listed in the Pharmaceutical Schedule	
Simvastatin							
Tab 10 mg	9,262,901	\$2,572,308	\$0.2777		C H 1%	There is a confidential rebate associated with simvastatin	
Tab 20 mg	44,310,135	\$14,963,533	\$0.3377		C H 1%	There is a confidential rebate associated with simvastatin	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Simvastatin					
Tab 40 mg	35,910,872	\$21,546,523	\$0.6000	C H 1%	There is a confidential rebate associated with simvastatin
Tab 80 mg	2,077,816	\$1,454,471	\$0.7000	C H 1%	There is a confidential rebate associated with simvastatin
Cardiovascular System					
Amiodarone Hydrochloride					
Inj 50 mg per ml, 3 ml	3,045	\$18,526	\$6.0840	C H 1%	
Amlodipine					
Tab 2.5 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule
<u>Tab 5 mg</u>	2,136,658	\$559,163	\$0.2617	C H 1%	
<u>Tab 10 mg</u>	773,076	\$350,435	\$0.4533	C H 1%	
Bendrofluazide					
Tab 1.25 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule
Tab 2.5 mg	29,720,783	\$802,461	\$0.0270	C H 1%	
Tab 5 mg	3,516,135	\$151,194	\$0.0430	C H 1%	
Bumetanide					
Inj 500 mcg per ml, 4 ml			\$1.5900	C H 1%	
Tab 1 mg	702,728	\$114,966	\$0.1636	C H 1%	
Clonidine					
<u>Inj 150 mcg per ml, 1 ml</u>	7,106	\$19,897	\$2.8000	C H 1%	
<u>Tab 25 mcg</u>				H 1%	
<u>Tab 150 mcg</u>	498,503	\$151,196	\$0.3033	C H 1%	
<u>TDDS 2.5 mg, 100 mcg per day</u>				H 1%	
<u>TDDS 5 mg, 200 mcg per day</u>				H 1%	
<u>TDDS 7.5 mg, 300 mcg per day</u>				H 1%	
Felodipine					
Tab long-acting 2.5 mg	7,868,000	\$2,722,328	\$0.3460	C H 1%	
Tab long-acting 5 mg	13,936,666	\$2,554,591	\$0.1833	C H 1%	
Tab long-acting 10 mg	9,447,736	\$2,519,711	\$0.2667	C H 1%	
Flecainide Acetate					
Cap long-acting 100 mg	622,030	\$887,823	\$1.4273	C H 1%	
Cap long-acting 200 mg	465,021	\$1,172,318	\$2.5210	C H 1%	
Inj 10 mg per ml, 15 ml	17	\$167	\$9.8040	C H 1%	
Oral liq				C H 1%	Not currently listed on the Pharmaceutical Schedule
Tab 50 mg	252,342	\$180,096	\$0.7137	C H 1%	
Tab 100 mg	264,329	\$333,187	\$1.2605	C H 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Glyceryl Trinitrate							
Spray 400 mcg per dose	27,874,641	\$574,218	\$0.0206		C H 1%		
Tab 600 mcg					C H 1%	Note this product has been recently discontinued	
TDDS 5 mg	203,467	\$124,786	\$0.6133		C H 1%		
TDDS 10 mg	84,047	\$68,641	\$0.8167		C H 1%		
Isosorbide Mononitrate							
Tab 20 mg	720,981	\$129,777	\$0.1800		C H 1%		
Tab long-acting 40 mg	930,458	\$460,298	\$0.4947		C H 1%		
Losartan							
Tab 12.5 mg	1,390,462	\$1,105,000	\$0.7947		+ C H 1%	There is a rebate associated with losartan	
Tab 25 mg					+ C H 1%	Not currently listed in the Pharmaceutical Schedule	
Tab 50 mg	1,884,413	\$1,996,912	\$1.0597		+ C H 1%	There is a rebate associated with losartan	
Tab 100 mg	48,255	\$56,941	\$1.1800		+ C H 1%	There is a rebate associated with losartan	
Losartan with Hydrochlorothiazide							
Tab 50 mg with hydrochlorothiazide 12.5 mg	401,260	\$425,215	\$1.0597		+ C H 1%	There is a rebate associated with losartan with hydrochlorothiazide	
Methyldopa							
<u>Tab 125 mg</u>	118,665	\$10,680	\$0.0900		C H 1%		
<u>Tab 250 mg</u>	591,604	\$75,725	\$0.1280		C H 1%		
<u>Tab 500 mg</u>	145,971	\$28,464	\$0.1950		C H 1%		
Metoprolol Succinate							
Tab long-acting 23.75 mg	11,326,501	\$1,962,883	\$0.1733		C H 1%		
Tab long-acting 47.5 mg	27,687,737	\$5,999,933	\$0.2167		C H 1%		
Tab long-acting 95 mg	21,320,420	\$7,958,913	\$0.3733		C H 1%		
Tab long-acting 190 mg	5,464,913	\$3,688,816	\$0.6750		C H 1%		
Mexiletine Hydrochloride							
<u>Cap 50 mg</u>	120,285	\$28,291	\$0.2352		C H 1%		
<u>Cap 200 mg</u>	84,220	\$46,363	\$0.5505		C H 1%		
Nifedipine							
Tab long-acting 30 mg	541,911				C H 1%		
Tab long-acting 60 mg	226,362				C H 1%		
Oxyntifylline							
Tab 400 mg	51,359	\$37,944	\$0.7388	*	C H 1%		
Phentolamine Mesylate							
Inj 10 mg per ml, 1 ml	517	\$1,858	\$3.5940	*	C H 1%		
Propafenone Hydrochloride							
Tab 150 mg	84,439	\$69,071	\$0.8180		C H 1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Quinapril							
<u>Tab 5 mg</u>	9,952,014	\$783,224	\$0.0787		C H	1%	
<u>Tab 10 mg</u>	14,354,067	\$1,560,287	\$0.1087		C H	1%	
<u>Tab 20 mg</u>	17,626,152	\$2,525,828	\$0.1433		C H	1%	
Quinapril with Hydrochlorothiazide							
<u>Tab 10 mg with hydrochlorothiazide 12.5 mg</u>	2,116,789	\$237,715	\$0.1123		C H	1%	
<u>Tab 20 mg with hydrochlorothiazide 12.5 mg</u>	5,351,415	\$815,021	\$0.1523		C H	1%	
Trandolapril							
Cap 1 mg	36,268	\$3,964	\$0.1093	*	C H	1%	
Cap 2 mg	46,194	\$7,308	\$0.1582	*	C H	1%	
Tab 4 mg					C H	1%	Not currently listed in the Pharmaceutical Schedule
Triamterene with Hydrochlorothiazide							
Tab 50 mg with hydrochlorothiazide 25 mg	488,921	\$24,446	\$0.0500		C H	1%	
Verapamil Hydrochloride							
<u>Tab long-acting 120 mg</u>	2,037,006	\$123,850	\$0.0608		C H	1%	
Dermatologicals							
Acitretin							
<u>Cap 10 mg</u>	263,457	\$249,626	\$0.9475		C H	1%	
<u>Cap 25 mg</u>	81,678	\$166,378	\$2.0370		C H	1%	
Aqueous Cream							
Crm (100 g or less)					C H	1%	This pack size is not currently listed in Section B of the Pharmaceutical Schedule
<u>Crm (greater than 100 g)</u>	115,023,572	\$540,611	\$0.0047		C H	1%	
Betamethasone Valerate							
<u>Crm 0.1%</u>	4,498,594	\$152,952	\$0.0340		C H	1%	
Lotn 0.1%	219,295	\$44,078	\$0.2010		C H	1%	
<u>Oint 0.1%</u>	1,436,315	\$48,835	\$0.0340		C H	1%	
Betamethasone Valerate with Clioquinol							
Crm 0.1% with clioquinol 3%	112,480	\$26,174	\$0.2327	*	C H	1%	
Oint 0.1% with clioquinol 3%	38,883	\$9,048	\$0.2327	*	C H	1%	
Betamethasone Valerate with Fusidic Acid							
Crm 0.1% with fusidic acid 2%	432,227	\$100,579	\$0.2327	*	C H	1%	
Calcipotriol							
Crm 50 mcg per g (pack size 30 g or less)	1,339,336	\$1,001,823	\$0.7480		C H	1%	Volume is aggregated for all pack sizes of calcipotriol cream
Crm 50 mcg per g (pack size greater than 30 g)	1,339,336	\$1,001,823	\$0.7480		C H	1%	Volume is aggregated for all pack sizes of calcipotriol cream

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Calcipotriol							
Oint 50 mcg per g (pack size 30 g or less)	1,509,702	\$1,129,257	\$0.7480		C H	1%	Volume is aggregated for all pack sizes of calcipotriol ointment
Oint 50 mcg per g (pack size greater than 30 g)	1,509,702	\$1,129,257	\$0.7480		C H	1%	Volume is aggregated for all pack sizes of calcipotriol ointment
Soln 50 mcg per ml (pack size 30 ml or less)	340,124	\$254,753	\$0.7490		C H	1%	Volume is aggregated for all pack sizes of calcipotriol solution
Soln 50 mcg per ml (pack size greater than 30 ml)	340,124	\$254,753	\$0.7490		C H	1%	Volume is aggregated for all pack sizes of calcipotriol solution
Chlorhexidine Gluconate							
<u>Soln 4%</u>	1,988,107	\$28,629	\$0.0144		C H	1%	
Clobetasone Butyrate							
Crn 0.05% (pack size 30 g or less)	800,150	\$143,467	\$0.1793		C H	1%	
Crn 0.05% (pack size greater than 30 g)	669,433	\$120,029	\$0.1793	*	C H	1%	
Clotrimazole							
<u>Crn 1%</u>	1,741,881	\$47,902	\$0.0275		C H	1%	
Soln 1%	10,386	\$2,264	\$0.2180	*	C H	1%	
Emulsifying Ointment							
<u>Oint BP</u>	32,769,451	\$252,325	\$0.0077		C H	1%	
Fluorouracil Sodium							
Crn 5%	273,829	\$327,089	\$1.1945	*	C H	1%	
Hydrocortisone							
Crn 0.5% (pack size greater than 100 g)					C H	1%	Not currently listed in the Pharmaceutical Schedule
Crn 1% (pack size 100 g or less)	15,744,933	\$384,176	\$0.0244		C H	1%	Volume is aggregated for all pack sizes of hydrocortisone cream
Crn 1% (pack size greater than 100 g)	29,257,598	\$713,885	\$0.0244		C H	1%	Volume is aggregated for all pack sizes of hydrocortisone cream
<u>Powder</u>			\$1.5056		C H	1%	
Hydrocortisone with Wool Fat and Mineral Oil							
<u>Lotn 1% with wool fat hydrous 3% and mineral oil</u>	10,426,268	\$414,965	\$0.0398		C		
Ketoconazole							
<u>Shampoo 2%</u>	3,350,447	\$131,673	\$0.0393		C H	1%	
Magnesium Sulphate							
Paste	154,218	\$5,737	\$0.0372	*	C H	1%	
Miconazole Nitrate							
<u>Crn 2%</u>	1,284,360	\$37,632	\$0.0293		C H	1%	
Lotn 2%	18,085	\$2,628	\$0.1453	*	C H	1%	
Tincture 2%	35,417	\$5,146	\$0.1453	*	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name		Units	Cost	Unit Subsidy		DV Limit	Comments
Line Item							
Mometasone Furoate							
Crn 0.1% (pack size 30 g or less)		2,376,935	\$627,511	\$0.2640	C H	1%	Volume is aggregated for all pack sizes of mometasone furoate cream. There is a confidential rebate associated with mometasone
Crn 0.1% (pack size greater than 30 g)		2,417,520	\$638,225	\$0.2640	C H	1%	Volume is aggregated for all pack sizes of mometasone furoate cream. There is a confidential rebate associated with mometasone
Oint 0.1% (pack size 30 g or less)		1,944,976	\$513,474	\$0.2640	C H	1%	Volume is aggregated for all pack sizes of mometasone furoate ointment. There is a confidential rebate associated with mometasone
Oint 0.1% (pack size greater than 30 g)		1,896,240	\$500,607	\$0.2640	C H	1%	Volume is aggregated for all pack sizes of mometasone furoate ointment. There is a confidential rebate associated with mometasone
Lotn 0.1%		239,341	\$38,295	\$0.1600	C H	1%	There is a confidential rebate associated with mometasone
Oil in Water Emulsion							
Crn		35,021,248	\$196,119	\$0.0056	C H	1%	
Podophyllotoxin							
Soln 0.5%		19,467	\$177,985	\$9.1429 *	C H	1%	
Sunscreen							
Crn or Lotn		14,083			C		
Tar with Triethanolamine Lauryl Sulphate and Fluorescein							
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>		39,375,539	\$181,127	\$0.0046	C H	1%	
Topical anti-acne treatment							
Lotn					C		Sole supply could also be awarded for a gel, crn and/or liq preparation. This Line Item includes topical benzoyl peroxide, retinoid and tretinoin products. Not currently listed in the Pharmaceutical Schedule.
Triamcinolone Acetonide							
<u>Crn 0.02%</u>		468,062	\$30,190	\$0.0645	C H	1%	
<u>Oint 0.02%</u>		167,482	\$10,803	\$0.0645	C H	1%	
Triamcinolone Acetonide with Gramicidin, Neomycin and Nystatin							
Crn 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g		518,437	\$120,640	\$0.2327 *	C H	1%	
<u>Oint 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g</u>		269,242	\$53,848	\$0.2000	C H	1%	
Urea							
<u>Crn 10%</u>		9,950,000	\$250,740	\$0.0252	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Wool Fat with Mineral Oil					
Lotn hydrous 3% with mineral oil	11,692,772	\$65,480	\$0.0056 *	C H 1%	A range of pack sizes are required for this line item
Zinc					
Crm BP	169,067	\$2,215	\$0.0131 *	C H 1%	
Zinc and Castor Oil					
<u>Oint BP</u>	9,645,382	\$98,383	\$0.0102	C	

Extemporaneously Compounded Preparations and Galenicals

Acetylcysteine

Inj 200 mg per ml, 10 ml	388	\$5,318	\$13.7060 *	C H 1%
--------------------------	-----	---------	-------------	--------

Sodium Bicarbonate

Powder BP			\$0.0240	C H 1%
-----------	--	--	----------	--------

Genito-Urinary System

Clotrimazole

Pessaries 500 mg with applicator				C H 1%	Not currently listed in the Pharmaceutical Schedule
----------------------------------	--	--	--	--------	-----------------------------------------------------

Diaphragm

<u>Diaphragm</u>	1,037	\$44,487	\$42.9000	C
------------------	-------	----------	-----------	---

Intra-Uterine Device

IUD	8,414	\$332,353	\$39.5000	C	Sole supply may be awarded to a range of sizes
-----	-------	-----------	-----------	---	------------------------------------------------

Miconazole Nitrate

Pessaries 100 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
------------------	--	--	--	--------	-----------------------------------------------------

Vaginal crm 2% with applicator	499,473	\$34,364	\$0.0688 *	C H 1%
--------------------------------	---------	----------	------------	--------

Norethisterone with Mestranol

Tab 1 mg with mestranol 50 mcg and 7 inert tab	74,841	\$5,897	\$0.0788 *	C
------------------------------------------------	--------	---------	------------	---

Oestriol

Crm 1 mg per g with applicator	1,508,863	\$704,186	\$0.4667	C
--------------------------------	-----------	-----------	----------	---

Pessaries 500 mcg	256,243	\$123,842	\$0.4833	C
-------------------	---------	-----------	----------	---

Papaverine Hydrochloride

Inj 12 mg per ml, 10 ml	1,552	\$22,696	\$14.6240	C H 1%
-------------------------	-------	----------	-----------	--------

Hormone Preparations - Systemic Excluding Contraceptive Hormones

Cabergoline

Tab 0.5 mg	68,070	\$893,759	\$13.1300	C H 1%
------------	--------	-----------	-----------	--------

Calcitonin

Inj 100 iu per ml, 1 ml	690	\$13,800	\$20.0000	C H 1%
-------------------------	-----	----------	-----------	--------

Carbimazole

Tab 5 mg	2,364,515	\$255,368	\$0.1080	C H 1%
----------	-----------	-----------	----------	--------

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Desmopressin							
Inj 4 mcg per ml, 1 ml	1,911	\$12,838	\$6.7180	C H	1%		
Inj 15 mcg per ml, 1 ml				H	1%		
<u>Nasal spray 10 mcg per dose</u>	82,036	\$414,282	\$5.0500	C H	1%		
Nasal drops 100 mcg per ml	6,682	\$104,319	\$15.6120	C H	1%		
Fludrocortisone Acetate							
Tab 100 mcg	830,319	\$63,270	\$0.0762	C H	1%		
Gestrinone							
Cap 2.5 mg	8,824	\$112,363	\$12.7338	C H	1%		
Hydrocortisone							
Crm 0.5% (pack size 100 g or less)				C H	1%	Not currently listed in the Pharmaceutical Schedule	
Methylprednisolone Acetate							
<u>Inj 40 mg per ml, 1 ml</u>	5,595	\$33,738	\$6.0300	C H	1%		
Methylprednisolone Acetate with Lignocaine							
<u>Inj 40 mg per ml with lignocaine 1 ml</u>	2,339	\$14,104	\$6.0300	C H	1%		
Norethisterone							
<u>Tab 5 mg</u>	1,246,493	\$311,623	\$0.2500	C H	1%		
Oestradiol							
Tab 1 mg	974,213	\$143,307	\$0.1471 *	C			
Tab 2 mg	674,594	\$130,129	\$0.1929 *	C			
TDDS 3.9 mg (releases 50 mcg of oestradiol per day)	53,406	\$55,008	\$1.0300 *	C			
TDDS 7.8 mg (releases 100 mcg of oestradiol per day)	17,092	\$30,125	\$1.7625 *	C			
TDDS 25 mcg per day	45,430	\$17,091	\$0.3762 *	C			
TDDS 50 mcg per day	44,382	\$22,857	\$0.5150 *	C			
TDDS 100 mcg per day	12,429	\$10,952	\$0.8812 *	C			
Oestradiol valerate							
Tab 1 mg	211,560	\$31,120	\$0.1471 *	C			
Tab 2 mg	387,803	\$74,807	\$0.1929	C			
Oestradiol with levonorgestrel							
Tab 2 mg with 75 mcg levonorgestrel (36) and tab 2 mg oestradiol (48)	149,526	\$28,844	\$0.1929	C			
Oestradiol with norethisterone							
Tab 1 mg with 0.5 mg norethisterone acetate	1,148,192	\$221,486	\$0.1929 *	C			
Tab 2 mg with 1 mg norethisterone acetate	536,350	\$103,462	\$0.1929 *	C			
Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg oestradiol tab (12) and 1 mg oestradiol tab (6)	325,257	\$62,742	\$0.1929 *	C			
Oestriol							
Tab 2 mg	191,602	\$44,701	\$0.2333	C			

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Oestrogens					
Conjugated, equine tab 300 mcg	1,207,489	\$129,805	\$0.1075 *	C	
Conjugated, equine tab 625 mcg	1,896,813	\$279,021	\$0.1471 *	C	
Oestrogens with medroxyprogesterone					
Tab 625 mcg conjugated equine (28) and 5 mg medroxyprogesterone acetate tab (28)	257,702	\$49,711	\$0.1929 *	C	
Tab 625 mcg conjugated equine (28) and 2.5 mg medroxyprogesterone acetate tab (28)	181,489	\$35,009	\$0.1929 *	C	
Pamidronate Disodium					
<u>Inj 3 mg per ml, 5 ml</u>	50	\$2,425	\$48.5000	C H	1%
<u>Inj 3 mg per ml, 10 ml</u>	4,717	\$318,398	\$67.5000	C H	1%
<u>Inj 6 mg per ml, 10 ml</u>	323	\$43,605	\$135.0000	C H	1%
<u>Inj 9 mg per ml, 10 ml</u>				H	1%
Prednisone					
<u>Tab 1 mg</u>	9,007,276	\$178,344	\$0.0198	C H	1%
<u>Tab 2.5 mg</u>	1,578,885	\$35,999	\$0.0228	C H	1%
<u>Tab 5 mg</u>	9,488,780	\$210,651	\$0.0222	C H	1%
<u>Tab 20 mg</u>	3,723,012	\$227,476	\$0.0611	C H	1%
Testosterone Cypionate					
Inj long-acting 100 mg per ml, 10 ml	446	\$27,389	\$61.4100	C H	1%
Testosterone Enanthate					
Inj long-acting 250 mg - pre-filled syringe	4,725	\$70,875	\$15.0000	C H	1%
Testosterone Esters					
Inj 250 mg per ml, 1 ml	11,936	\$154,929	\$12.9800	C H	1%
Testosterone Undecanoate					
Cap 40 mg	770,666	\$779,760	\$1.0118	C H	1%
Tetracosactrin					
Inj 250 mcg	142	\$2,516	\$17.7180	C H	1%
Inj 1 mg per ml, 1 ml	227	\$6,102	\$26.8800	C H	1%
Triamcinolone Acetonide					
Inj 10 mg per ml, 1 ml	3,976	\$8,835	\$2.2220	C H	1%
Inj 10 mg per ml, 5 ml	83	\$856	\$10.3100	C H	1%
Inj 40 mg per ml, 1 ml	54,507	\$306,220	\$5.6180	C H	1%

Infections - Agents for Systemic Use

Amoxicillin

Drops 125 mg per 1.25 ml	266,390	\$96,566	\$0.3625	C H	1%
<u>Inj 250 mg</u>	714	\$902	\$1.2640	C H	1%
<u>Inj 500 mg</u>	1,884	\$2,724	\$1.4460	C H	1%
<u>Inj 1 g</u>	9,037	\$19,881	\$2.2000	C H	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Amoxicillin Clavulanate							
Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml	13,450,940	\$369,901	\$0.0275	C H	1%		
Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml	16,854,482	\$800,588	\$0.0475	C H	1%		
Tab amoxicillin 500 mg with potassium clavulanate 125 mg	14,266,399	\$4,565,248	\$0.3200	C H	1%		
Benzylpenicillin Sodium (Penicillin G)							
Inj 600 mg	12,573	\$8,789	\$0.6990	C H	1%		
Cefazolin Sodium							
<u>Inj 500 mg</u>	1,767	\$2,403	\$1.3600	C H	1%		
<u>Inj 1 g</u>	5,298	\$9,854	\$1.8600	C H	1%		
Cefepime hydrochloride							
<u>Inj 1 g, 15 ml</u>				H	1%		
<u>Inj 2 g, 77 ml</u>				H	1%		
Cefotaxime							
<u>Inj 500 mg</u>				H	1%		
<u>Inj 1 g</u>				H	1%		
Inj 2 g				H	1%		
Cefoxitin Sodium							
Inj 1 g	939	\$9,142	\$9.7360	C H	1%		
Ceftazidime							
Inj 250 mg				H	1%		
Inj 500 mg				H	1%		
Inj 1 g				H	1%		
Inj 2 g				H	1%		
Ceftriaxone Sodium							
Inj 250 mg	714			C H	1%		Note this product has been recently discontinued
<u>Inj 500 mg</u>	385	\$1,536	\$3.9900	C H	1%		
<u>Inj 1 g</u>	1,808	\$9,763	\$5.4000	C H	1%		
<u>Inf 2 g</u>				H	1%		
Cefuroxime Axetil							
Tab 250 mg	6,897	\$13,622	\$1.9750	C H	1%		
Cefuroxime Sodium							
Inj 250 mg			\$2.0970	C H	1%		
Inj 750 mg	136	\$653	\$4.8000	C H	1%		
Inj 1.5 g			\$12.3600	C H	1%		
Cephalexin Monohydrate							
Grans for oral liq 125 mg per 5 ml				C H	1%		Not currently listed in the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Cephalexin Monohydrate							
Grans for oral liq 250 mg per 5 ml					C H 1%	Not currently listed in the Pharmaceutical Schedule	
Ciprofloxacin							
<u>Tab 250 mg</u>	223,855	\$40,764	\$0.1821		C H 1%		
<u>Tab 500 mg</u>	984,019	\$292,057	\$0.2968		C H 1%		
<u>Tab 750 mg</u>	45,652	\$31,468	\$0.6893		C H 1%		
Clindamycin							
<u>Cap hydrochloride 150 mg</u>	353,481	\$251,643	\$0.7119		C H 1%		
<u>Inj phosphate 150 mg per ml, 4 ml</u>	1,384	\$26,919	\$19.4500		C H 1%		
Co-Trimoxazole							
<u>Oral liq sugar-free trimethoprim 40 mg and sulphamethoxazole 200 mg per 5 ml</u>	9,838,261	\$116,091	\$0.0118		C H 1%		
<u>Tab trimethoprim 80 mg and sulphamethoxazole 400 mg</u>	2,591,235	\$88,102	\$0.0340		C H 1%		
Dicloxacillin							
Cap 250 mg	37,318	\$3,840	\$0.1029	*	C H 1%		
Cap 500 mg	78,509	\$12,530	\$0.1596	*	C H 1%		
Grans for oral liq 125 mg per 5 ml	53,795	\$1,910	\$0.0355	*	C H 1%		
Inj 500 mg			\$1.0900		C H 1%		
Inj 1 g			\$1.5080		C H 1%		
Doxycycline Hydrochloride							
Tab 50 mg	735,699	\$71,142	\$0.0967	*	C H 1%		
Tab 100 mg	6,020,003	\$195,048	\$0.0324		C H 1%		
Erythromycin Ethyl Succinate							
<u>Grans for oral liq 200 mg per 5 ml</u>	6,876,661	\$257,875	\$0.0375		C H 1%		
<u>Grans for oral liq 400 mg per 5 ml</u>	3,819,134	\$213,872	\$0.0560		C H 1%		
Erythromycin Lactobionate							
Inj 300 mg	83	\$1,178	\$14.1940		C H 1%		
Inj 1 g	293	\$1,905	\$6.5000		C H 1%		
Erythromycin Stearate							
Tab 250 mg	245,762	\$36,741	\$0.1495	*	C H 1%		
Tab 500 mg	168,288	\$50,318	\$0.2990	*	C H 1%		
Flucloxacillin Sodium							
Inj 250 mg	56	\$52	\$0.9320		C H 1%		
Inj 500 mg	2,142	\$2,335	\$1.0900		C H 1%		
Inj 1 g	44,171	\$66,610	\$1.5080		C H 1%		
Fluconazole							
<u>Cap 50 mg</u>	134,602	\$69,710	\$0.5179		C H 1%		
<u>Cap 150 mg</u>	56,232	\$219,305	\$3.9000		C H 1%		
<u>Cap 200 mg</u>	17,684	\$26,209	\$1.4821		C H 1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Fusidic Acid							
Inj 500 mg sodium fusidate per 10 ml			\$12.8700	*	C H	1%	
Gentamicin Sulphate							
Inj 10 mg per ml, 1 ml	95	\$163	\$1.7120		C H	1%	
Powder					H	1%	
Isoniazid							
Tab 100 mg with rifampicin 150 mg	21,858	\$19,681	\$0.9004		C H	1%	
Tab 150 mg with rifampicin 300 mg	94,249	\$169,243	\$1.7957		C H	1%	
Mebendazole							
Oral liq 100 mg per 5 ml	51,909	\$7,542	\$0.1453	*	C H	1%	
Tab 100 mg	13,060	\$8,250	\$0.6317	*	C H	1%	
Metronidazole							
<u>Inj 500 mg, 100 ml</u>					H	1%	
Oral liq benzoate 200 mg per 5 ml	196,452	\$49,113	\$0.2500	*	C H	1%	
Suppos 500 mg	2,037	\$4,987	\$2.4480		C H	1%	
Suppos 1 g	2,806	\$9,347	\$3.3310		C H	1%	
Minocycline Hydrochloride							
Cap 100 mg	679,262	\$131,233	\$0.1932	*	C H	1%	
Tab 50 mg	1,893,729	\$182,745	\$0.0965	*	C H	1%	
Norfloxacin							
<u>Tab 400 mg</u>	925,075	\$297,319	\$0.3214		C H	1%	
Ornidazole							
Tab 500 mg	141,338	\$174,976	\$1.2380		C H	1%	
Piperacillin Sodium with Tazobactam Sodium							
Inf 2 g with tazobactam sodium 250 mg					H	1%	
Inf 4 g with tazobactam sodium 500 mg					H	1%	
Procaine Penicillin							
<u>Inj 1.5 mega u</u>	3,486	\$33,187	\$9.5200		C H	1%	
Rifampicin							
Cap 150 mg	40,762	\$23,911	\$0.5866		C H	1%	
Cap 300 mg	102,692	\$125,654	\$1.2236		C H	1%	
Oral liq 100 mg per 5 ml	99,786	\$21,055	\$0.2110		C H	1%	
Tab 600 mg	19,728	\$75,229	\$3.8133		C H	1%	
Stavudine (d4T)							
Oral soln 1 mg per ml			\$0.5038		+ C H	1%	
Teicoplanin							
Inj 200 mg					H	1%	
Inj 400 mg					H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Terbinafine						
<u>Tab 250 mg</u>	2,550,859	\$1,275,430	\$0.5000	C H	1%	
Tobramycin						
Inj 40 mg per ml, 2 ml	36,689	\$201,790	\$5.5000	C H	1%	
Powder				H	1%	
Trimethoprim						
Oral liq				C H	1%	
<u>Tab 300 mg</u>	1,090,902	\$172,363	\$0.1580	C H	1%	
Vancomycin Hydrochloride						
Cap 125 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule
Cap 250 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule
<u>Inj 50 mg per ml, 10 ml</u>	2,261	\$10,627	\$4.7000	C H	1%	
Voriconazole						
Inj 200 mg				H	1%	
Tab 50 mg				H	1%	
Tab 200 mg				H	1%	
Zidovudine (AZT)						
Cap 100 mg	38,376	\$111,290	\$2.9000	+ C H	1%	
Inj 200 mg per ml, 20 ml				+ H	1%	
Oral liq 10 mg per ml	176,034	\$51,050	\$0.2900	+ C H	1%	
Musculo-skeletal System						
Allopurinol						
<u>Tab 100 mg</u>	11,110,012	\$254,419	\$0.0229	C H	1%	
<u>Tab 300 mg</u>	7,898,573	\$334,899	\$0.0424	C H	1%	
Auranofin						
Tab 3 mg	13,022	\$14,973	\$1.1498	* C H	1%	
Diclofenac Sodium						
Inj 25 mg per ml, 3 ml	23,595	\$56,628	\$2.4000	C H	1%	
Suppos 12.5 mg	7,606	\$1,407	\$0.1850	C H	1%	
Suppos 25 mg	12,794	\$2,840	\$0.2220	C H	1%	
Suppos 50 mg	68,492	\$26,301	\$0.3840	C H	1%	
Suppos 100 mg	165,224	\$105,082	\$0.6360	C H	1%	
Ibuprofen						
<u>Tab 200 mg</u>	15,751,556	\$280,378	\$0.0178	C H	1%	
Tab 400 mg	711,101	\$25,386	\$0.0357	* C H	1%	
Tab 600 mg	190,872	\$10,154	\$0.0532	* C H	1%	
Indomethacin						
<u>Cap 25 mg</u>	353,454	\$20,854	\$0.0590	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Indomethacin						
Cap 50 mg	861,816	\$59,896	\$0.0695	C H	1%	
Cap long-acting 75 mg	638,272	\$84,890	\$0.1330	C H	1%	
Suppos 100 mg	48,678	\$23,526	\$0.4833	C H	1%	
Naproxen						
Tab long-acting 750 mg	754,179	\$150,836	\$0.2000	C H	1%	
Tab long-acting 1,000 mg	714,613	\$166,719	\$0.2333	C H	1%	
Orphenadrine Citrate						
Inj 30 mg per ml, 2 ml	64	\$205	\$3.2000 *	C H	1%	
Tab 100 mg	1,106,615	\$205,166	\$0.1854	C H	1%	
Probenecid						
Tab 500 mg	307,760	\$169,268	\$0.5500	C H	1%	
Pyridostigmine Bromide						
Tab 60 mg	348,269	\$119,526	\$0.3432	C H	1%	
Tenoxicam						
Inj 10 mg per ml, 2 ml	83,861	\$167,722	\$2.0000	C H	1%	
Suppos 20 mg	10,459	\$5,543	\$0.5300	C H	1%	
Tiaprofenic Acid						
Cap long-acting 300 mg	291,076	\$19,589	\$0.0673 *	C H	1%	
Tab 300 mg	67,739	\$4,552	\$0.0672 *	C H	1%	
Nervous System						
Amantadine Hydrochloride						
Cap 100 mg	423,125	\$337,146	\$0.7968	C H	1%	
Amisulpride						
Tab 50 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 100 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 200 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 400 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Amitriptyline						
Tab 10 mg	13,117,576	\$393,527	\$0.0300	C H	1%	
Tab 25 mg	7,489,485	\$254,642	\$0.0340	C H	1%	
Tab 50 mg	1,904,738	\$99,046	\$0.0520	C H	1%	
Benzotropine Mesylate						
Tab 2 mg	967,710	\$116,899	\$0.1208	C H	1%	
Bromocriptine Mesylate						
Tab 2.5 mg	351,803	\$112,858	\$0.3208	C H	1%	
Tab 10 mg	41,602	\$50,280	\$1.2086	C H	1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Bupivacaine Hydrochloride with Adrenaline						
Inj 0.25% with 1:400,000 of adrenaline, 10 ml					H	1%
Inj 0.25% with 1:400,000 of adrenaline, 20 ml					H	1%
Inj 0.5% with 1:200,000 of adrenaline, 10 ml					H	1%
Inj 0.5% with 1:200,000 of adrenaline, 20 ml					H	1%
Bupivacaine Hydrochloride with Fentanyl						
<u>Inj 0.125% with 2 mcg fentanyl per ml, 15 ml</u>					H	1%
<u>Inj 0.125% with 2 mcg fentanyl per ml, 20 ml</u>					H	1%
<u>Inf 0.125% with 2 mcg fentanyl per ml, 100 ml</u>					H	1%
<u>Inf 0.125% with 2 mcg fentanyl per ml, 200 ml</u>					H	1%
Citalopram Hydrobromide						
Tab 20 mg	18,286,429	\$2,285,804	\$0.1250		C H	1%
Clomipramine Hydrochloride						
Tab 10 mg	290,050	\$29,005	\$0.1000		C H	1%
Tab 25 mg	1,871,532	\$97,320	\$0.0520		C H	1%
Clonazepam						
Inj 1 mg per ml, 1 ml	12,278	\$22,984	\$1.8720		C H	1%
Oral drops 2.5 mg per ml	105,259	\$77,681	\$0.7380		C H	1%
<u>Tab 500 mcg</u>	5,144,280	\$282,421	\$0.0549		C H	1%
<u>Tab 2 mg</u>	1,014,611	\$100,954	\$0.0995		C H	1%
Cyclizine Lactate						
<u>Inj 50 mg per ml, 1 ml</u>	77,903	\$232,930	\$2.9900		C H	1%
Desipramine Hydrochloride						
Tab 25 mg	198,131	\$128,072	\$0.6464 *		C H	1%
Diazepam						
Inj 5 mg per ml, 2 ml	18,572	\$34,321	\$1.8480		C H	1%
Rectal tubes 5 mg	16,347	\$86,639	\$5.3000		C H	1%
Rectal tubes 10 mg	17,430	\$112,877	\$6.4760		C H	1%
Tab 2 mg	2,260,085	\$37,969	\$0.0168		C H	1%
Tab 5 mg	2,452,165	\$49,043	\$0.0200		C H	1%
Tab 10 mg	597,865	\$20,626	\$0.0345		C H	1%
Dihydrocodeine Tartrate						
<u>Tab long-acting 60 mg</u>	4,918,209	\$2,483,696	\$0.5050		C H	1%
Doxepin Hydrochloride						
Cap 10 mg	1,804,270	\$90,033	\$0.0499		C H	1%
Cap 25 mg	2,181,009	\$91,384	\$0.0419 *		C H	1%
Cap 50 mg	685,643	\$47,926	\$0.0699		C H	1%
Cap 75 mg	337,838	\$37,128	\$0.1099		C H	1%

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Entacapone					
Tab 200 mg	208,674	\$269,189	\$1.2900	C H 1%	
Gelatin Plasma Replacer					
<u>Inf 3.5%, 500 ml bag</u>				H 1%	
<u>Inf 4%, 500 ml bag</u>				H 1%	
Hyoscine (Scopolamine)					
Patches, 1.5 mg	3,948	\$18,871	\$4.7800 *	C H 1%	
Hyoscine Hydrobromide					
Inj 400 mcg per ml, 1 ml	7,387	\$9,839	\$1.3320	C H 1%	
Ketamine hydrochloride					
Inj 200 mg				H 1%	
Inj 1 g				H 1%	
Ketorolac					
Inj 10 mg per ml				C H 1%	Not currently listed in the Pharmaceutical Schedule
Tab 10 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
Levodopa with Carbidopa					
Tab 100 mg with carbidopa 25 mg	3,539,914	\$707,983	\$0.2000	C H 1%	There is a rebate associated with levodopa with carbidopa
Tab 250 mg with carbidopa 25 mg	188,846	\$108,586	\$0.5750	C H 1%	There is a rebate associated with levodopa with carbidopa
Tab long-acting 200 mg with carbidopa 50 mg	1,893,158	\$1,325,211	\$0.7000	C H 1%	There is a rebate associated with levodopa with carbidopa
Lisuride Hydrogen Maleate					
Tab 200 mcg	216,716	\$198,664	\$0.9167	C H 1%	
Methadone Hydrochloride					
Inj 10 mg per ml, 1 ml	28,038	\$145,798	\$5.2000	C H 1%	
Metoclopramide Hydrochloride					
<u>Inj 5 mg per ml, 2 ml</u>	214,702	\$107,351	\$0.5000	C H 1%	
Midazolam					
Tab 7.5 mg	385,162	\$39,980	\$0.1038 *	C H 1%	
Mirtazapine					
Tab 15 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
Tab 30 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
Tab 45 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule
Morphine Sulphate					
Inj 10 mg per ml, 1 ml	191,366	\$181,798	\$0.9500	C H 1%	
Inj 20 mg per ml, 1 ml				C H 1%	Not currently listed on the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Morphine Sulphate						
<u>Inj 10 mg per ml 10 ml prefilled syringe</u>					H 1%	
Inj 30 mg per ml, 1 ml	74,863	\$77,259	\$1.0320	C H	1%	
<u>Inj 30 mg per ml 30 ml prefilled syringe</u>				H	1%	
<u>Inj 50 mg per ml 50 ml prefilled syringe</u>				H	1%	
<u>Inj 60 mg per ml 30 ml prefilled syringe</u>				H	1%	
Suppos 5 mg			\$1.4783	C H	1%	
Suppos 10 mg	44	\$41	\$0.9233	C H	1%	
Suppos 20 mg	108	\$183	\$1.6925	C H	1%	
Suppos 30 mg	3,232	\$8,454	\$2.6158	C H	1%	
Tab long-acting 10 mg	812,089	\$146,176	\$0.1800	C H	1%	
Tab long-acting 30 mg	388,097	\$139,715	\$0.3600	C H	1%	
Tab long-acting 60 mg	193,966	\$139,656	\$0.7200	C H	1%	
Tab long-acting 100 mg	257,132	\$218,562	\$0.8500	C H	1%	
Nefopam Hydrochloride						
Tab 30 mg	967,393	\$251,522	\$0.2600	C H	1%	
Nitrazepam						
Tab 5 mg	813,433	\$16,269	\$0.0200 *	C H	1%	
Nortriptyline Hydrochloride						
<u>Tab 10 mg</u>	2,900,419	\$147,921	\$0.0510	C H	1%	
<u>Tab 25 mg</u>	6,036,700	\$421,362	\$0.0698	C H	1%	
Ondansetron hydrochloride						
Inj 2 mg per ml, 2 ml				H	1%	
Inj 2 mg per ml, 4 ml				H	1%	
Orphenadrine Hydrochloride						
Tab 50 mg	429,819	\$54,888	\$0.1277	C H	1%	
Paracetamol						
<u>Oral liq 120 mg per 5 ml</u>	117,913,035	\$825,391	\$0.0070	C H	1%	
<u>Oral liq 250 mg per 5 ml</u>	119,028,006	\$868,904	\$0.0073	C H	1%	
<u>Suppos 125 mg</u>	74,760	\$24,334	\$0.3255	C H	1%	
<u>Suppos 250 mg</u>	82,289	\$51,513	\$0.6260	C H	1%	
<u>Tab 500 mg</u>	169,011,852	\$1,554,909	\$0.0092	C H	1%	
Paracetamol with Codeine						
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	28,667,405	\$928,824	\$0.0324	C H	1%	
Pentastarch Plasma Expander						
<u>Inf 10%, 500 ml bag</u>				H	1%	
Pergolide						
Tab 0.05 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Pergolide							
<u>Tab 0.25 mg</u>	246,165	\$174,777	\$0.7100	C H	1%		
<u>Tab 1 mg</u>	50,469	\$138,285	\$2.7400	C H	1%		
Pethidine Hydrochloride							
Inj 50 mg per ml, 1 ml	26,804	\$20,103	\$0.7500	C H	1%		
Inj 50 mg per ml, 1.5 ml			\$0.8700	C H	1%		
Inj 50 mg per ml, 2 ml	80,992	\$67,709	\$0.8360	C H	1%		
Pimozide							
Tab 2 mg	157,684	\$46,422	\$0.2944	C H	1%		
Tab 4 mg			\$0.5890	C H	1%		
Tab 10 mg				C H	1%		Not currently listed in the Pharmaceutical Schedule
Prochlorperazine							
Inj 12.5 mg per ml, 1 ml	30,862	\$46,015	\$1.4910 *	C H	1%		
Suppos 5 mg	6,599	\$12,564	\$1.9040 *	C H	1%		
Suppos 25 mg	13,508	\$33,878	\$2.5080 *	C H	1%		
Tab 3 mg buccal	305,139	\$36,434	\$0.1194 *	C H	1%		
Sertraline							
Tab 50 mg				C	1%		Not currently listed in the Pharmaceutical Schedule
Tab 100 mg				C	1%		Not currently listed in the Pharmaceutical Schedule
Streptokinase							
<u>Inj 1,500,000 IU</u>				H	1%		
<u>Inj 250,000 IU</u>				H	1%		
Sulpiride							
Tab 200 mg				C H	1%		Not currently listed on the Pharmaceutical Schedule
Tab 400 mg				C H	1%		Not currently listed on the Pharmaceutical Schedule
Temazepam							
<u>Tab 10 mg</u>	4,578,761	\$144,689	\$0.0316	C H	1%		
Tetrabenazine							
Tab 25 mg	117,065	\$253,984	\$2.1696	C H	1%		
Thioridazine Hydrochloride							
Tab 10 mg	239,925	\$18,330	\$0.0764	C H	1%		
Tab 25 mg	331,899	\$28,942	\$0.0872	C H	1%		
Tab 50 mg	161,660	\$19,141	\$0.1184	C H	1%		
Tab 100 mg	93,146	\$17,735	\$0.1904	C H	1%		
Tolcapone							
Tab 100 mg	172,413	\$221,982	\$1.2875	C H	1%		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Tramadol hydrochloride					
<u>Cap 50 mg</u>				H 1%	
<u>Inj 50 mg per ml, 1 ml</u>				H 1%	
<u>Inj 50 mg per ml, 2 ml</u>				H 1%	
<u>Tab sustained release 100 mg</u>				H 1%	
<u>Tab sustained release 150 mg</u>				H 1%	
<u>Tab sustained release 200 mg</u>				H 1%	
Triazolam					
<u>Tab 125 mcg</u>	1,614,028	\$82,315	\$0.0510	C H 1%	
<u>Tab 250 mcg</u>	2,530,217	\$103,739	\$0.0410	C H 1%	
Trimipramine Maleate					
<u>Cap 25 mg</u>	831,275	\$45,720	\$0.0550	C H 1%	
<u>Cap 50 mg</u>	460,978	\$47,020	\$0.1020	C H 1%	
Zopiclone					
<u>Tab 7.5 mg</u>	12,087,924	\$535,495	\$0.0443	C H 1%	

Oncology Agents and Immunosuppressants

Anastrozole

Tab 1 mg	713,664	\$3,484,108	\$4.8820	* + C H 1%	
----------	---------	-------------	----------	------------	--

Azathioprine

Inj 50 mg			\$46.3300	* C H 1%	
-----------	--	--	-----------	----------	--

Bleomycin sulphate

<u>Inj 15,000 iu</u>				H PCT 1%	
----------------------	--	--	--	----------	--

Calcium Folate

Inj 3 mg			\$3.4200	C H PCT 1%	
<u>Inj 50 mg</u>	125	\$950	\$7.6000	C H PCT 1%	
<u>Inj 100 mg</u>				H PCT 1%	
<u>Inj 300 mg</u>				H PCT 1%	
<u>Inj 1 g</u>				H PCT 1%	
Tab 15 mg	1,735	\$11,085	\$6.3890	C H PCT 1%	

Cyclophosphamide

Inj 1 g				C H PCT 1%	
Inj 2 g				H PCT 1%	

Daunorubicin

Inj 20 mg				H PCT 1%	
-----------	--	--	--	----------	--

Etoposide Phosphate

Inj 100 mg (of etoposide base)				H PCT 1%	
--------------------------------	--	--	--	----------	--

Fludarabine phosphate

<u>Inj 50 mg</u>				H PCT 1%	
<u>Tab 10 mg</u>				H PCT 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name	Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Ifosfamide						
	Inj 1 g				H PCT 1%	
	Inj 2 g				H PCT 1%	
Letrozole						
	Tab 2.5 mg	261,995	\$1,279,060	\$4.8820 *	C H 1%	
Lomustine						
	Cap 10 mg				H PCT 1%	
	Cap 40 mg				H PCT 1%	
Mercaptopurine						
	Tab 50 mg	144,715	\$272,412	\$1.8824	C H PCT 1%	
Mesna						
	Tab 400 mg				H PCT 1%	
	Tab 600 mg				H PCT 1%	
Methotrexate						
	Inj 2.5 mg per ml, 2 ml	99	\$468	\$4.7300	C H PCT 1%	
	Inj 25 mg per ml, 2 ml	3,556	\$32,786	\$9.2200	C H PCT 1%	
	Inj 25 mg per ml, 20 ml	151	\$12,118	\$80.2500	C H PCT 1%	
	<u>Inj 100 mg per ml, 10 ml</u>			\$33.0000	C H PCT 1%	
	<u>Inj 100 mg per ml, 50 ml</u>			\$150.0000	C H PCT 1%	
Mitomycin C						
	Inj 10 mg				H PCT 1%	
	Inj 2 mg				H PCT 1%	
Octreotide (somatostatin analogue)						
	Inj 50 mcg per ml, 1 ml	2,822	\$24,551	\$8.7000	C H 1%	
	Inj 100 mcg per ml, 1 ml	7,692	\$124,610	\$16.2000	C H 1%	
	Inj 500 mcg per ml, 1 ml	472	\$37,666	\$79.8000	C H 1%	
	LAR 10 mg pre-filled syringe	180	\$319,050	\$1,772.5000	C H 1%	
	LAR 20 mg pre-filled syringe	834	\$1,967,198	\$2,358.7500	C H 1%	
	LAR 30 mg pre-filled syringe	506	\$1,493,333	\$2,951.2500	C H 1%	
Paclitaxel						
	<u>Inj 30 mg</u>				H PCT 1%	
	<u>Inj 100 mg</u>				H PCT 1%	
	<u>Inj 150 mg</u>				H PCT 1%	
	<u>Inj 300 mg</u>				H PCT 1%	
	Inj 600 mg				H PCT 1%	
Teniposide						
	Inj 10 mg per ml, 5 ml				H PCT 1%	
Thalidomide						
	Cap 50 mg				H PCT 1%	

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name

Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Vinblastine Sulphate					
Inj 10 mg			\$27.5000	C H PCT 1%	

Respiratory System and Allergies

Aminophylline

Inj 25 mg per ml, 10 ml	4,134	\$10,616	\$2.5680	C H	1%
-------------------------	-------	----------	----------	-----	----

Budesonide

Metered aqueous nasal spray, 50 mcg per dose	4,652,037	\$54,894	\$0.0118 *	C H	1%
Metered aqueous nasal spray, 100 mcg per dose	23,644,628	\$307,380	\$0.0130 *	C H	1%

Cetirizine Hydrochloride

<u>Oral liq 1 mg per ml</u>	1,962,144	\$53,959	\$0.0275	C H	1%
<u>Tab 10 mg</u>	7,882,071	\$290,848	\$0.0369	C H	1%

Fexofenadine Hydrochloride

Tab 30 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule
Tab 60 mg	69,395	\$15,059	\$0.2170 *	C H	1%	
Tab 120 mg	114,122	\$54,094	\$0.4740 *	C H	1%	
Tab 180 mg				C H	1%	Not currently listed on the Pharmaceutical Schedule

Ipratropium Bromide

<u>Aerosol inhaler, 20 mcg per dose CFC-free</u>	13,660,343	\$1,106,488	\$0.0810	C H	1%
--------------------------------------------------	------------	-------------	----------	-----	----

Nedocromil

Aerosol Inhaler, 2 mg per dose CFC-free	797,876	\$165,240	\$0.2071 *	C H	1%
-----------------------------------------	---------	-----------	------------	-----	----

Promethazine Hydrochloride

Inj 25 mg per ml, 2 ml	11,889	\$19,141	\$1.6100	C H	1%
<u>Tab 10 mg</u>	806,222	\$44,342	\$0.0550 *	C H	1%
<u>Tab 25 mg</u>	741,368	\$66,723	\$0.0900 *	C H	1%

Theophylline

Tab long-acting 250 mg	1,201,057	\$258,347	\$0.2151	C H	1%
Tab long-acting 350 mg	295,820	\$86,616	\$0.2928	C H	1%

Sensory Organs

Acetazolamide

Sodium inj 500 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule
<u>Tab 250 mg</u>	338,087	\$29,583	\$0.0875	C H	1%	

Aciclovir

Eye oint 3%	19,808	\$165,199	\$8.3400	C H	1%
-------------	--------	-----------	----------	-----	----

Atropine Sulphate

<u>Eye drops 1%</u>	74,531	\$19,922	\$0.2673	C H	1%
---------------------	--------	----------	----------	-----	----

Betaxolol Hydrochloride

Eye drops 0.25%	84,599	\$199,654	\$2.3600	C H	1%
-----------------	--------	-----------	----------	-----	----

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Betaxolol Hydrochloride							
Eye drops 0.5%	10,486	\$15,729	\$1.5000		C H	1%	
Bimatoprost							
Eye Drops 0.03%	75,320	\$489,580	\$6.5000		C H	1%	
Brimonidine tartrate							
<u>Eye Drops 0.2%</u>	137,809	\$246,678	\$1.7900		C H	1%	
Brinzolamide							
Eye Drops 1%	110,115	\$215,165	\$1.9540		C H	1%	
Dexamethasone with Framycetin and Gramicidin							
Ear/Eye drops 500 mcg with framycetin sulphate 5 mg and gramicidin 50 mcg per ml	823,461	\$463,197	\$0.5625	*	C		
Dexamethasone with Neomycin and Polymyxin B Sulphate							
Eye drops 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per ml	98,582	\$88,724	\$0.9000		C		
Eye oint 0.1% with neomycin sulphate 0.35% and polymyxin B sulphate 6,000 u per g	12,613	\$19,424	\$1.5400		C		
Diclofenac Sodium							
Eye drops 1 mg per ml	28,705	\$79,226	\$2.7600		C H	1%	Single dose presentation would not be a DV Pharmaceutical
Flumetasone Pivalate							
Ear drops 0.02% with clioquinol 1%	126,618	\$75,300	\$0.5947	*	C		
Fusidic Acid							
Eye drops 1%	222,560	\$200,304	\$0.9000	*	C H	1%	
Hypromellose							
<u>Eye drops 0.3%</u>	839,852	\$146,722	\$0.1747		C H	1%	
<u>Eye drops 0.5%</u>	53,081	\$6,333	\$0.1193		C H	1%	
Latanoprost							
Eye drops 50 mcg per ml	402,406	\$3,138,767	\$7.8000	*	C H	1%	
Levocabastine							
Eye drops 0.5 mg per ml	113,594	\$247,351	\$2.1775	*	C H	1%	
Lodoxamide trometamol							
Eye drops 0.1%	165,937	\$144,531	\$0.8710		C H	1%	
Naphazoline Hydrochloride							
<u>Eye drops 0.1%</u>	92,914	\$25,709	\$0.2767		C H	1%	
Pilocarpine							
<u>Eye drops 0.5%</u>	7,891	\$1,678	\$0.2127		C		
<u>Eye drops 1%</u>	28,487	\$6,153	\$0.2160		C		
<u>Eye drops 2%</u>	86,403	\$24,884	\$0.2880		C		
Eye drops 2% single dose	587	\$938	\$1.5975	*	C		
<u>Eye drops 3%</u>	1,063	\$454	\$0.4273		C		
<u>Eye drops 4%</u>	30,993	\$13,575	\$0.4380		C		

SCHEDULE ONE: PHARMACEUTICALS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Pilocarpine						
Eye drops 6%	5,074	\$2,896	\$0.5707		C	
Polyvinyl Alcohol						
Eye drops 1.4%	238,572	\$57,567	\$0.2413		C	
Eye drops 3%	59,023	\$15,269	\$0.2587		C	
Sodium Cromoglycate						
Eye drops 2%	411,262	\$135,305	\$0.3290		C	
Sulphacetamide Sodium						
Eye drops 10%	38,809				C H	1%
Travoprost						
Eye drops 0.004%	87,048	\$678,974	\$7.8000		C H	1%

Special Foods

Food Thickner

Powder	1,724,917				C	
--------	-----------	--	--	--	---	--

Protein Supplement

Powder	297,677	\$10,448	\$0.0351		C	Sole supply could be awarded for a single or range of flavours from one supplier
--------	---------	----------	----------	--	---	----------------------------------------------------------------------------------